Please use this identifier to cite or link to this item:
|Title:||Positron emission tomography: Evolving modalities, radiopharmaceuticals and professional collaboration||Authors:||Ayesa, Sally ;Murphy, Andrew||Affliation:||Central Coast Local Health District
|Issue Date:||Dec-2022||Source:||69(4):415-418||Journal title:||Journal of Medical Radiation Sciences||Department:||Radiology||Abstract:||Positron emission tomography (PET) as an imaging modality has undergone considerable innovation over the past few decades. Hybrid anatomical and functional imaging has become commonplace (initially PET/CT but now also PET/MRI) with improvements in imaging technology continually delivering studies with increasing diagnostic accuracy and decreasing radiation dose to the patient. More and more radiopharmaceuticals have emerged from the research sphere into clinical practice, with the traditional PET workhorse tracer 18 F-FDG accompanied by a range of novel radiopharmaceuticals with specific molecular targets. Imaging facilities offering PET/CT and PET/MRI provide a unique collaborative environment for the medical imaging multidisciplinary team. Diagnostic radiographers and nuclear medicine technologists especially have the opportunity to not only work together but also share knowledge and technical skills, ultimately benefitting the quality of patient care.||URI:||https://hdl.handle.net/1/2341||DOI:||10.1002/jmrs.629||Pubmed:||https://pubmed.ncbi.nlm.nih.gov/36334076||Publicaton type:||Journal Article||Keywords:||Radiology
|Appears in Collections:||Radiology|
Show full item record
checked on May 31, 2023
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.